![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Exova Grp | LSE:EXO | London | Ordinary Share | GB00BKY7HG11 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 238.50 | 239.00 | 239.75 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMEXO
RNS Number : 2115C
Exova Group PLC
11 April 2017
STOCK EXCHANGE RELEASE
11 April 2017
Exova Group plc
Exova acquires SL Pharma Labs Incorporated
Exova Group plc ("Exova") EXO.L, the global testing, calibration and advisory services provider, has acquired SL Pharma Labs Incorporated (SL Pharma), a Delaware, US, based business that provides laboratory and clinical manufacture testing services to pharmaceutical, biotechnology and medical device companies.
Founded in 1997, SL Pharma has built a strong reputation in the provision of high value and high quality pharmaceutical product development and testing services focused primarily on the development and clinical manufacture of parenteral, ophthalmic, intranasal and topical drug products. The business has a team of 14 specialists and achieved revenues of around $2.5m in 2016.
Ian El-Mokadem, Chief Executive Officer at Exova, said: "This acquisition complements our existing operations by enhancing Exova's technical expertise in pharmaceutical services and offers a great foundation for further growth in North America. SL Pharma's addition to our portfolio clearly demonstrates our commitment to providing more technically demanding services and developing our capabilities in new markets."
ENDS
Enquiries:
Andy Jones
Powerscourt
T: +44 (0) 20 7549 0747
E: andy.jones@exova.com
Andrew Pickup
Corporate Affairs Director, Exova Group plc
T: +44 (0) 7920 243 393
E: andrew.pickup@exova.com
Exova
Exova is one of the world's leading laboratory-based testing groups, trusted by organisations to test and advise on the safety, quality and performance of their products and operations. Headquartered in Edinburgh, UK, Exova operates 135 laboratories and offices in 33 countries and employs around 4,200 people throughout Europe, the Americas, the Middle East, Asia/Asia Pacific and Africa.
Exova's capabilities help to extend asset life, bring predictability to applications, and shorten the time to market for customers' products, processes and materials. With over 90 years' experience, Exova specialises in testing across a number of key sectors ranging from Aerospace to Fire & Building Products; Oil & Gas and Industrials; Infrastructure & Environment; Transportation; and Health Sciences.
Exova Group plc is registered in England (registration number 08907086). Its legal entity identifier ('LEI') number is 213800BFE317FGSYMZ19.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQBBGDSSGBBGRB
(END) Dow Jones Newswires
April 11, 2017 10:30 ET (14:30 GMT)
1 Year Exova Chart |
1 Month Exova Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions